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Abstract
Background: To evaluate the presence of myocardial structural alterations and subtle myocardial dysfunction during
familial screening in asymptomatic mutation carriers without hypertrophic cardiomyopathy (HCM) phenotype.
Methods and Findings: Sixteen HCM families with pathogenic mutation were studied and 46 patients with phenotype
expression (Mut+/Phen+) and 47 patients without phenotype expression (Mut+/Phen2) were observed. Twenty-five control
subjects, matched with the Mut+/Phen2 group, were recruited for comparison. Echocardiography was performed to
evaluate conventional parameters, myocardial structural alteration by calibrated integrated backscatter (cIBS) and global
and segmental longitudinal strain by speckle tracking analysis. All 3 groups had similar left ventricular dimensions and
ejection fraction. Basal anteroseptal cIBS was the highest in Mut+/Phen+ patients (214.064.6 dB, p,0.01) and was higher
in Mut+/Phen2 patients as compared to controls (217.062.3 vs. 222.662.9 dB, p,0.01) suggesting significant myocardial
structural alterations. Global and basal anteroseptal longitudinal strains (28.464.0%, p,0.01) were the most impaired in
Mut+/Phen+ patients as compared to the other 2 groups. Although global longitudinal strain was similar between Mut+/
Phen2 group and controls, basal anteroseptal strain was lower in Mut+/Phen2 patients (214.163.8%, p,0.01) as
compared to controls (219.962.9%, p,0.01), suggesting a subclinical segmental systolic dysfunction. A combination of
.219.0 dB basal anteroseptal cIBS or .218.0% basal anteroseptal longitudinal strain had a sensitivity of 98% and a
specificity of 72% in differentiating Mut+/Phen2 group from controls.
Conclusion: The use of cIBS and segmental longitudinal strain can differentiate HCM Mut+/Phen2 patients from controls
with important clinical implications for the family screening and follow-up of these patients.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common
inherited cardiac disease and is the leading cause of sudden cardiac
death in young individuals. [1] It is caused by genetic mutations
encoding sarcomere proteins and the clinical diagnosis is character-
ized by unexplained left ventricular hypertrophy (LVH). However,
HCMphenotypic expression is extremely variable and somepatients
may show only mild LVH or normal left ventricular (LV) thickness.
[2,3] Genetic testing for pathogenic mutations allows for a certain
diagnosis and identification of HCM mutation carriers before,
and independent of, the development of LVH. However, genetic
testing, due to the large HCM genetic heterogeneity, is complex,
time-consuming and expensive. Therefore, novel and sensitive
diagnostic tests are needed for cascade family screening in order to
identify HCM patients at an early stage.
Initial studies using tissue Doppler imaging (TDI) showed that
mutation carriers without an overt HCM phenotype may have
subtle myocardial diastolic dysfunction, as an early marker of the
disease. [4–7] However, reported sensitivity and specificity of TDI
to identify HCM mutation carriers were highly variable. [4,5,7] In
addition, although an increased collagen synthesis has been
demonstrated in HCM mutation carriers without a typical
HCM phenotype, [8] the relation between early myocardial
dysfunction and structural alterations remains unknown.
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Ultrasonic tissue characterization with calibrated integrated
backscatter (IBS) enables the evaluation of myocardial structural
alterations in HCM patients, identifying the presence of myocar-
dial disarray and diffuse myocardial fibrosis. [9] In addition,
myocardial strain assessment based on two-dimensional (2D)
speckle tracking analysis is a novel echocardiographic approach
for a sensitive and angle-independent evaluation of myocardial
global and regional systolic dysfunction. [10] The aim of this study
was therefore to assess global and regional myocardial structural
alterations (by calibrated IBS analysis) and systolic dysfunction (by
speckle tracking strain analysis) in HCM mutation carriers without
overt phenotype.
Methods
Patient Population and Protocol
A total of 16 unrelated HCM patients with an identified gene
mutation referred to the cardio-genetic out-patient clinic of our
Department were included and their 1st degree relatives were
offered genetic screening. The genetic testing protocol was
approved by the Internal Review Board of our Institution (Leiden
University Medical Center) and written informed consent was
provided from all subjects undergoing genetic testing.
Pathogenic HCM gene mutations were found in 77 1st degree
relatives subsequently referred for detailed evaluation including
clinical assessment, 12-lead electrocardiography (ECG), exercise
testing, Holter monitoring and transthoracic echocardiography.
The echocardiographic examination included conventional LV
measures, calibrated IBS for the assessment of myocardial
structural alteration and 2D speckle tracking myocardial strain
analysis. Ambulatory 24-hour ECG Holter monitoring was also
performed in 67 (87%) 1st degree relatives to document the
presence of ventricular arrhythmias. Clinical and echocardio-
graphic data were prospectively collected in electronic patient
dossier (EPD-Vision version 8.3.3.6; Leiden, The Netherlands).
The diagnosis of HCM was based on the criteria proposed by
McKenna et al. for adult members of affected families, [2,3,11]
which includes both echocardiographic and ECG criteria, for the
identification of patients with emerging or mild HCM. As shown
in Figure 1, a total of 30 relatives fulfilled the criteria for HCM
phenotype and, together with the 16 index patients, were included
in the phenotype positive group (Mut+/Phen+). The remaining 47
relatives were considered as mutation carriers without phenotype
expression (Mut+/Phen2).
In addition, 25 individuals matched for age and gender with the
Mut+/Phen2 group were consecutively selected as a control
group from an existing echocardiographic database with this
information. These subjects were referred for atypical chest pain,
palpitations, or syncope without murmur, and showed normal
structural heart on echocardiography.
Subsequently, both myocardial structural alteration and systolic
dysfunction were compared among these 3 groups.
Standard Echocardiography
All patients were imaged using a commercially available system
(Vivid 7, General Electric-Vingmed, Horton, Norway). Images
were obtained using a 3.5-MHz transducer and digitally stored;
offline analysis was performed using EchoPAC version 108.1.5
(General Electric – Vingmed). Maximum thickness of LV walls
was measured in diastole from the basal, mid and apical short-axis
views and from the parasternal long-axis view. [12] LV
dimensions, LV volumes and ejection fraction were measured
using the modified biplane Simpson’s rule. [13]
Evaluation of LV diastolic function was based on recommen-
dation from the American Society of Echocardiography. [14] As
previously described, [15] LV diastolic function was classified
according to 4 categories: normal and diastolic dysfunction
grade 1, 2, 3 and 4. Early diastolic velocity (E`) of the lateral
mitral valve annulus was measured by TDI and E/E` ratio was
calculated as a validated estimation of LV filling pressure. [16]
Calibrated Integrated Backscatter (IBS)
Calibrated IBS evaluates myocardial ultrasound reflectivity,
providing an estimate of myocardial structural alterations and
fibrotic content. [10,17] The IBS measurements were obtained
from the parasternal long-axis view. As shown in Figure 2, a
969 mm region of interest was positioned in the mid-myocardium
of the basal segment of LV anteroseptal and posterior walls, and a
263-mm region of interest was positioned in the pericardium for
reference. The measurements of IBS intensity were performed at
end-diastole and expressed in decibels (dB). Calibrated IBS was
calculated by subtracting pericardial IBS intensity from myocar-
dial IBS intensity of the LV. A less negative value suggested a
greater myocardial structural alteration.
Two-dimensional Speckle Tracking Strain Analysis
The measurement of global longitudinal, circumferential and
radial strain using 2D speckle tracking analysis has been described
previously. [18] Briefly, longitudinal strain was measured from 3
apical views (2 walls per view). Each wall was divided into 3 levels
(basal, mid and apical) and subsequently 18 segmental strain
curves were obtained. Global longitudinal strain was calculated as
the average of peak systolic strain values of the 18 segments. In
addition, peak longitudinal systolic strain of the basal segment of
anteroseptal and posterior walls were evaluated as shown in
Figure 3. These specific LV segments were chosen to allow a direct
comparison with the IBS measurements (performed in the same
regions) and to specifically explore the myocardial function of the
basal anteroseptum, which is the predominant region of LV wall
thickening. [19]
The global values of circumferential and radial strain were
derived from the average of the peak systolic strain values
obtained from the mid-ventricular short-axis view (divided into
6 segments).
Statistical Analysis
Continuous variables are presented as mean(standard devia-
tion). Categorical data are presented as frequencies and percent-
ages. One-way analysis of variance (ANOVA) with post-hoc test by
Bonferroni was used to examine the differences among groups.
Receiver operator characteristic (ROC) curve analysis was
performed to determine the accuracy of calibrated IBS, segmental
longitudinal strain and E` velocity in differentiating Mut+/Phen2
patients from the controls. The optimal cut-off value was defined
as the maximized value for the sum of sensitivity and specificity.
To test the variability of calibrated IBS and regional longitudinal
strain, 6 Mut+/phen2 and 6 Mut+/Phen2 patients were select-
ed. A first observer analyzed a first dataset twice (within 1 month
time) to determine intra-observer agreement. To test inter-
observer variability, the measurements were repeated by a second
experienced observer on the same dataset. The first observer also
analyzed a second dataset acquired the same day of the first one in
order to evaluate test-retest variability. Bland-Altman analysis was
conducted (expressed as mean difference62SD), and intraclass
correlation coefficients (ICC) were calculated as indicators of
reproducibility. All statistical analysis were performed using the
statistical package SPSS for windows (Version 16.0, SPSS,
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Chicago, USA). A p value ,0.05 was considered to be statistically
significant.
Results
Clinical and Conventional Echocardiographic
Characteristics
Clinical characteristics of all patients and normal controls are
summarized in Table 1. The majority of Mut+/Phen2 and Mut+/
Phen+ patients had one of the Dutch founder mutations in the
Myosin Binding Protein C (MYBPC3) gene (C2373dupG). [20] By
design, age and gender were comparable between controls and
Mut+/Phen2 patients. In few Mut+/Phen2 and Mut+/Phen+
patients, significant coronary artery disease was discovered during
the clinical assessment; importantly, all patients were treated with
complete revascularization and none of them had previous myocar-
dial infarction or evidence of regional wall motion abnormalities.
LV dimensions and ejection fraction were similar among all 3
groups (Table 2). The anteroseptal and posterior wall thickness in
the Mut+/Phen+ group were the thickest among all 3 groups and
were comparable between the Mut+/Phen2 groups and controls.
LV diastolic dysfunction was more common in the Mut+/Phen+
and Mut+/Phen2 groups as compared with controls. In addition,
E` velocity was lower and LV filling pressures (estimated by E/E`)
were higher in the Mut+/Phen+ group than the other 2 groups.
Importantly, E` velocity was lower in the Mut+/Phen2 group as
compared to controls.
Calibrated IBS
As shown in Figure 4, structural alterations over the basal
anteroseptal region evaluated by calibrated IBS were most
predominant in the Mut+/Phen+ group (214.064.6 dB) as
compared to the Mut+/Phen2 group (217.062.3 dB; p,0.01)
and controls (222.662.9 dB; p,0.01). Importantly, the basal
anteroseptal calibrated IBS of the Mut+/Phen2 group was
significantly higher as compared to controls (p,0.01). Also at
the level of the basal posterior wall the degree of myocardial
structural alterations assessed by calibrated IBS was the highest in
the Mut+/Phen+ (219.665.1 dB) group as compared with the
Mut+/Phen2 group (222.567.4 dB, p = 0.04) and controls
(225.262.8 dB; p,0.01). However, the degree of myocardial
structural alterations was not significantly different between
Mut+/Phen2 group and controls (p = 0.21).
Speckle Tracking Strain Measurements
Global strain. Global longitudinal, circumferential and
radial strain were significantly impaired in the Mut+/Phen+
group as compared to the other 2 groups. On the other hand,
Mut+/Phen2 group showed similar values as compared to
controls (Table 2).
Segmental strain. As shown in Figure 5, regional strain
analysis at the level of the basal anteroseptal and posterior walls
was significantly different between the 3 groups. The basal
anteroseptal longitudinal strain was significantly impaired in the
Mut+/Phen+ group (28.464.0%) as compared to both Mut+/
Phen2 group (214.163.8%; p,0.01) and controls
Figure 1. Schematic representation of the individual diagnosis of hypertrophic cardiomyopathy (HCM) within the study
population, using the echocardiographic (Echo) and electrocardiographic (ECG) criteria proposed by McKenna et al10. The diagnosis
of HCM is made in the presence of 1 major criterion or of 2 minor Echo criteria or of 1 minor Echo +2 minor ECG criteria. A total of 46 mutation carriers
with phenotype expression (Mut+/Phen+) and 47 mutation carriers without phenotype expression (Mut+/Phen2) were identified.
doi:10.1371/journal.pone.0036115.g001
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Figure 2. Assessment of left ventricular (LV) myocardial structural alteration by calibrated integrated backscatter (IBS) in a
mutation carrier without HCM phenotype expression (Mut+/Phen2). A fixed region of interest is positioned at the level of the basal
anteroseptal wall (ASW, yellow circle), of the basal posterior wall (PW, blue circle) and in the pericardium (red circle, for calibration). The basal ASW
calibrated IBS of this Mut+/Phen2 patient was 214.4 dB and the basal PW calibrated IBS was 219.8 dB, indicating an altered myocardial structure.
doi:10.1371/journal.pone.0036115.g002
Figure 3. Example of impaired segmental strain measured by speckle tracking in the apical long-axis view (left panel), in a mutation
carrier without HCM phenotype expression. The basal anteroseptal wall (ASW) is colored in red, while the basal posterior wall (PW) is colored in
yellow. In the right panel, the corresponding longitudinal systolic strain curves: peak strain of basal ASW and PW are 214.8% and 224.8%
respectively, suggesting segmental systolic dysfunction of the ASW with a preserved function of the PW. Conversely, global longitudinal strain (white
dotted line) shows a normal value (219.8%) in the apical long-axis view.
doi:10.1371/journal.pone.0036115.g003
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(219.962.9%; p,0.01). Moreover, basal anteroseptal longitudi-
nal strain of the Mut+/Phen2 group was significantly lower as
compared to controls (p,0.01).
Similarly, the basal posterior longitudinal strain was impaired in
the Mut+/Phen+ group (216.465.5%) as compared to the Mut+/
Phen2 group (220.663.8%; p,0.01) and controls
(220.361.9%; p,0.01). However, no difference was noted in
the basal posterior longitudinal strain between Mut+/Phen2
group and controls.
Calibrated IBS and Segmental Speckle Tracking Strain
Measurements to Predict Mutation Carriers
The ROC curve was generated to determine the accuracy of
basal anteroseptal calibrated IBS, basal anteroseptal strain and E`
velocity measurements to differentiate the Mut+/Phen2 group
from controls (Figure 6). All 3 parameters significantly differen-
tiated Mut+/Phen2 group from controls, but the area under the
curve was higher for the basal anteroseptal calibrated IBS and
strain as compared to E` velocity. A cutoff value of .219.0 dB for
basal anteroseptal calibrated IBS provided a sensitivity of 89% and
specificity of 84%, while a cutoff value of .218.0% for basal
anteroseptal strain showed a sensitivity of 85% and specificity of
84%. For E` velocity, a cut-off value of ,10 cm/s yield a modest
sensitivity and specificity (62% and 60%, respectively).
A combination of .219.0 dB basal anteroseptal calibrated IBS
or .218.0% basal anteroseptal strain had a sensitivity of 98%, a
specificity of 72%, a positive predictive value of 87% and a
negative predictive value of 95%.
Holter Results and Clinical Outcomes in Mutation Carriers
Holter ECG recordings were analyzed taking into account
the percentage of premature ventricular contractions and the
presence of non-sustained ventricular tachycardia (NSVT)
defined as 3 or more consecutive ventricular beats at a rate
of .120 beats/min, lasting for ,30 s. Among the 47 Mut+/
Phen2 patients, 43(91%) underwent ECG Holter assessment
and 9 patients showed abnormal results defined by premature
ventricular contractions .100 per 24 hours (6 patients) and
NSVT (3 patients). [21]
A greater extent of myocardial structural alterations in the basal
anteroseptal wall, estimated by calibrated IBS (215.363.1 dB),
was observed in patients with abnormal Holter results as
compared to those with normal results (17.461.7 dB, p,0.01).
However, no significant difference was observed for calibrated IBS
of the basal posterior wall between these 2 groups (222.462.6
vs.222.568.1 dB, p= 0.96). Moreover, the segmental strain over
the basal anteroseptal wall (213.262.6 vs.214.2364.0%,
p= 0.47) and basal posterior wall (221.064.5 vs.220.563.7%,
p= 0.69) were also similar between these 2 groups.
Table 1. Baseline clinical characteristics of each group: controls, mutation carriers without phenotype expression (Mut+/Phen2),
and mutation carriers with phenotype expression (Mut+/Phen+).
Controls (n=25) Mut+/Phen2 (n =47) Mut+/Phen+ (n = 46)
Age, (SD) years 38(16) 42(17) 52(15)
Male, n (%) 14 (56) 24(51) 32(78)*
Identified mutation
MYBPC3
C2373dupG, n (%) 2 33 (70) 31 (65)
C1483C.G, n (%) 2 2 (4) 3 (7)
C2827C.T, n (%) 2 2 (4) 3 (7)
C927-2A.G, n (%) 2 2 (4) 3 (7)
MYH7
C1566T.A, n (%) 2 8 (17) 6 (13)
Cardiovascular medication
ACEI, n (%) 1 (4) 0 (0) 11 (23)
ARB, n (%) 0 (0) 2 (4) 1 (2)
CCB, n (%) 0 (0) 2 (4) 15 (33)
Diuretics, n (%) 0 (0) 1 (2) 4 (9)
Beta-blockers, n (%) 0 (0) 3 (6) 19 (43)
Cardiovascular risk factors
Hypertension 1 (4) 8 (17) 7 (15)
Diabetes mellitus 0 (0) 1(2) 1 (2)
Hyperlipidaemia 0 (0) 3 (6) 6 (13)
Smoking 4 (16) 3 (6) 2 (4)
Renal dysfunction 0 (0) 0 (0) 0 (0)
Coronary artery disease 0 (0) 3 (6) 1 (2)
Abbreviations: ACEI = angiotensin converting enzyme inhibitors; ARB = angiotensin receptor blocker; CCB = calcium channel blocker; MYBPC3 =myosin-binding protein
C; MYH7 = b-myosin heavy chain.
*Significant difference vs. controls and Mut+/Phen2.
doi:10.1371/journal.pone.0036115.t001
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Reproducibility
Inter-observer and intra-observer variability were evaluated by
two independent observers. The mean differences for intra-
observer variability for basal anteroseptal calibrated IBS was
0.160.2 dB (p= 0.72, ICC=0.99), for basal posterior calibrated
IBS was 0.260.4 dB (p = 0.78, ICC=0.99), for basal anteroseptal
strain was 0.260.4% (p= 0.17, ICC=0.99) and for basal posterior
anteroseptal strain was 0.261.1% (p= 0.19, ICC=0.99).
Mean absolute differences for inter-observer variability for basal
anteroseptal calibrated IBS was 0.561.5 dB (p = 0.09,
ICC=0.99), for basal posterior calibrated IBS was 0.361.2 dB
(p = 0.35, ICC=0.98), for basal anteroseptal strain was 0.662.0%
(p,0.01, ICC=0.97) and for basal posterior strain was 1.161.0%
(p= 0.35, ICC=0.99).
Test-retest reproducibility of calibrated IBS and segmental
strain were evaluated using a second echocardiographic dataset
acquired the same day. Mean absolute differences and coefficients
of variations between the 2 examinations were as follows: basal
anteroseptal calibrated IBS 0.460.2 dB p,0.01, ICC=0.99);
basal posterior calibrated IBS 0.360.7 dB (p,0.01, ICC=0.99);
basal anteroseptal strain 0.560.9% (p,0.01, ICC=0.99); basal
posterior strain 0.760.9% (p,0.01, r = 0.99).
Discussion
The results of the current study demonstrated that calibrated
IBS and 2D speckle tracking derived strain are able to detect
myocardial regional structural and functional abnormalities in
HCM mutation carriers without phenotype expression. In
particular, the combined measure of basal anteroseptal calibrated
IBS and longitudinal strain provided a highly sensitive index to
distinguish mutation carriers from normal controls.
Global LV Dysfunction in Mut+/Phen2 Patients
The advent of genetic testing has allowed the detection of
pathogenic gene mutations in family members of HCM patients
before the development of LVH or any HCM phenotype. In a
high percentage of HCM patients, the development of LVH is
delayed late into adulthood, especially in families with myosin-
binding protein C mutation. [2] However, genetic testing might
not be widely available due to the complex, time-consuming
and expensive laboratory techniques required. In addition, not
all (young) patients are motivated to have genetic analysis
performed, as financial institutions may limit their eligibility to
secure loans and insurance policies, even though they do not
have a HCM phenotype at that moment.
Therefore, several studies, using either echocardiography or
magnetic resonance imaging [4–7,22], have focused on the
ability to detect subtle myocardial dysfunction, which could be
applied to identify HCM mutation carriers without overt LVH.
These reports have demonstrated that mutation carriers without
LVH present an impaired LV diastolic function (mainly
measured by TDI) as compared with normal controls. [4–7]
Similarly, the current study showed that Mut+/Phen2 patients
had more frequent LV diastolic dysfunction and significantly
lower E` velocity as compared to controls. However, conflicting
Table 2. Echocardiographic characteristics of each group: controls, mutation carriers without phenotype expression (Mut+/
Phen2) and mutation carriers with phenotype expression (Mut+/Phen+).
Controls
(n=25)
Mut+/Phen2
(n = 47)
Mut+/Phen+
(n = 46)
ANOVA
p value
LV Dimensions and systolic function
LVEDD (SD), cm 4.6(0.3) 4.4(0.6) 4.5(0.7) 0.09
LVESD (SD), cm 2.9(0.3) 2.9(0.4) 2.9(0.7) 0.81
Anteroseptal wall thickness (SD), cm 0.98(0.14) 1.15(0.15) 2.01(0.54)*{ ,0.01
Posterior wall thickness (SD), cm 1.09(0.20) 1.14(0.22) 1.42(0.28)*{ ,0.01
LVEF (SD), % 67(4) 65(7) 66(9) 0.16
LVEDV (SD), ml 77.3(18.0) 79.7(23.0) 88.2(25.2) 0.09
LVESV (SD), ml 24.0(6.1) 28.2(14.1) 30.7(10.3) 0.06
Diastolic function
Grade: ,0.01
0, n (%) 20 (92.0) 35 (74.5) 20 (43.5)
1, n (%) 2 (8.0) 12 (25.5) 19 (41.3)
2, n (%) 0 (0) 0 (0) 4 (8.7)
3–4, n (%) 0 (0) 0 (0) 3 (6.5)
E` velocity (SD), cm/s 10.7(2.3) 9.0(2.9)* 5.8(2.7)*{ ,0.01
E/E`ratio (SD) 7.4(1.6) 11.5(4.3) 17.3(7.8)*{ ,0.01
Speckle tracking
Global Longitudinal strain (SD), % 221.3(1.3) 220.9(3.3) 215.2(3.7)*{ ,0.01
Global Circumferential strain (SD), % 221.2(3.7) 221.2(3.7) 215.9(3.6)*{ ,0.01
Global Radial strain (SD), % 39.2(10.7) 37.4(18.6) 26.4(11.0)*{ ,0.01
Abbreviations: LVEDD= left ventricular end-diastolic diameter; LVEDV= left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESD= left
ventricular end-systolic diameter; LVESV = left ventricular end-systolic volume; SD= standard deviation.
*Significant difference vs. Controls;
{Significant difference between Mut+/Phen2 and Mut+/Phen+ groups.
doi:10.1371/journal.pone.0036115.t002
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results are reported regarding the sensitivity and specificity of
this approach (due to a significant overlap with normal values)
and a definition of an accurate cut-off value to distinguish
HCM mutation carriers versus normal controls is lacking.
[4,5,7] Similarly in the current study, E` velocity showed only
modest sensitivity and specificity to differentiate Mut+/Phen2
patients from controls.
Besides the assessment of LV diastolic function, Ho and
colleagues have also evaluated LV global systolic function using
novel strain and strain rate imaging. [6] In their study, preclinical
HCM mutation carriers showed preserved LV global strain and
strain rate as compared to controls, while overt HCM patients
showed impaired LV global strain and strain rate, despite normal
LVEF and dimensions. Similarly in the present study, Mut+/
Phen2 patients showed values of LV global longitudinal, radial
and circumferential strain comparable to normal subjects.
Therefore, assessment of LV global systolic function seems not
able to distinguish between HCM mutation carriers and normal
controls.
Segmental Myocardial Structural Alterations and
Dysfunction in Mut+/Phen2 Patients
The present study showed that Mut+/Phen2 patients had a
significant increased calibrated IBS of the basal anteroseptal
region as compared to controls, suggesting substantial myocardial
structural alterations. The altered IBS values of the basal
anteroseptal region might reflect an increased myocardial inter-
stitial fibrosis in these patients, as recently suggested by Ho et al.,
who demonstrated increased myocardial type I collagen synthesis
in HCM mutation carriers without overt LVH. [9] However, the
authors did not observe any significant area of myocardial fibrosis
as assessed by delayed-enhancement magnetic resonance imaging
(MRI). An explanation for these findings might be the limited
resolution of this imaging technique to identify fine interstitial
fibrosis, especially over the basal anteroseptal region. [19]
Figure 4. Calibrated integrated backscatter (IBS) of the basal
anteroseptal and basal posterior walls in each group: controls,
mutation carriers without phenotype expression (Mut+/
Phen2) and mutation carriers with phenotype expression
(Mut+/Phen+). Structural alterations of the basal anteroseptum are
the greatest in the Mut+/Phen+ group, followed by Mut+/Phen2 group
and by controls. Similarly, structural alterations of the basal posterior
wall are the greatest in the Mut+/Phen+ group, but are similar between
the Mut+/Phen2 group and controls.
doi:10.1371/journal.pone.0036115.g004
Figure 5. Segmental strain measured by speckle tracking of the
basal anteroseptal and posterior walls in each group: controls,
mutation carriers without phenotype expression (Mut+/
Phen2) and mutation carrier with phenotype expression
(Mut+/Phen+). Basal anteroseptal strain is the most impaired in
Mut+/Phen+ group, followed by Mut+/Phen2 group and controls. Basal
posterior wall strain is the most impaired in Mut+/Phen+ group, while is
similar between Mut+/Phen2 group and controls.
doi:10.1371/journal.pone.0036115.g005
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In addition, ultrasonic techniques are sensitive to anisotropic
myocardial architecture, such as myocardial disarray (myocytes
arranged at oblique and perpendicular angles to each other),
which characterizes the myocardium of HCM patients. [23,24]
Mizuno and colleagues showed that calibrated IBS significantly
correlated with the degree of myocardial disarray and interstitial
fibrosis assessed by endomyocardial biopsy in HCM patients. [9]
Although the specificity may be lower than delayed-enhancement
MRI, calibrated IBS might provide a more sensitive technique to
assess subtle myocardial structural alterations in HCM mutation
carriers.
In addition to the structural abnormalities detected by
calibrated IBS, the current study showed that Mut+/Phen2
patients have also impaired segmental longitudinal strain in the
basal anteroseptal region, but not in the basal posterior region.
The preserved LV global strain values observed in the present
study in Mut+/Phen2 patients might be the result of compen-
sation from the remaining myocardial segments with normal
function.
The subtle segmental structural and functional alterations
circumscribed to the anteroseptum observed in Mut+/Phen2
patients can be explained by the preferential involvement of the
basal anteroseptal region by LVH in HCM disease. Previous
studies showed that in up to 96% of HCM patients, the anterior
portion of the ventricular septum is the most common site with
LVH as assessed by echocardiography. [25] In addition, a report
by Germans et al. has demonstrated using MRI that 81% of
mutation carriers had crypts located in the basal and mid septum
up to the subepicardium region. [26] Similarly, a recent report
using also MRI showed that hypertrophy usually involves the LV
with a segmental rather than global pattern, with the basal
anterior free wall and ventricular septum being the most
frequently affected. [19] Segmental subtle functional and struc-
tural alterations in mutation carriers may therefore anticipate the
development of hypertrophy in the same LV region, while global
LV function remains normal. In vitro studies have in fact
demonstrated that sarcomere protein mutations are associated
with impaired myocardial contractility, supporting the hypothesis
that subtle myocardial dysfunction precedes and promotes the
development of hypertrophy. [4,27,28] However, further longitu-
dinal studies are needed to describe the sequential phenotypic
changes of HCM patients.
Importantly, the current study showed that combined measure-
ments of basal anteroseptal calibrated IBS or longitudinal strain
have a high sensitivity and negative predictive value to distinguish
Mut+/Phen2 patients versus normal controls, suggesting a new
tool helping to identify subjects without mutation among familial
of HCM patients.
Clinical Outcome of Mut+/Phen2 Patients
Recent reports have suggested that mutation carriers without
clinical overt HCM frequently have risk factors for sudden cardiac
death. [29,30] In particular, NSVT occurred in 2.2–5.6% of
mutation carriers without clinical HCM. [29–31] Similarly in the
Figure 6. Receiver operator characteristic curve analysis to determine the accuracy of basal anteroseptal calibrated integrated
backscatter (IBS), and longitudinal strain and E` velocity to differentiate Mut+/Phen2 patients from controls. Basal anteroseptal
calibrated IBS .219.0 dB yielded a sensitivity of 89% and a specificity of 84% to differentiate Mut+/Phen2 patients from controls. Basal anteroseptal
strain .218.0% yielded a sensitivity of 85% and specificity of 84%. E` velocity ,10 cm/s provided a modest sensitivity of 62% and specificity of 60%
to differentiate Mut+/Phen2 patients from controls. AUC= area under the curve.
doi:10.1371/journal.pone.0036115.g006
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present cohort, NSVT detected by ECG Holter monitoring was
noted in 3 Mut+/Phen2 patients. These observations suggested
that mutation carriers are also at risk of developing ventricular
arrhythmias, even before the development of significant LVH. A
recent study by Christiaans et al. nonetheless showed that
mutation carriers have a low risk of sudden cardiac death before
the presence of LVH. [31] Therefore, future studies are required
to further explore the clinical characteristics as well as prognostic
outcome of these patients.
Limitations
Majority of patients in the current study had a mutation in the
MYBPC3 gene and therefore results cannot be extrapolated to
other groups of mutations (e.g. TNNT2, TPM1). Furthermore,
although the most likely mechanism behind an increased cIBS in
this population is the presence of myocardial structural alterations,
histopathological examination of the myocardium was not
available in the studied patients and the exact mechanism
generating the cIBS signals should be clarified in further specific
studies. In addition, the potential variation of cIBS and segmental
strain affected by age and coexisting disease, such as hypertension
and underlying coronary artery disease, could not be fully
evaluated due to the small study population and the relatively
low prevalence of these potential confounders. Larger study
populations involving HCM familial screening would be required
to further delineate the sensitivity and specificity of these
techniques to predict the presence of mutation and to confirm
the intra- and inter-observer reproducibility on a multi-center
setting. In particular, a specific evaluation should be performed to
better assess test-retest reproducibility, including multiple exam-
inations over time, and to explore possible differences among
vendors. Lastly, prospective follow-up is necessary to evaluate the
clinical significance of altered basal anteroseptal calibrated IBS
and longitudinal strain in Mut+/Phen2 patients.
Conclusion
Novel echocardiographic assessments by calibrated IBS and
speckle tracking derived strain allow detection of subtle myocardial
structural alterations and impaired systolic function in mutation
carriers without HCM phenotype. Importantly, the preferential
involvement of the basal anteroseptum demonstrated a segmental
rather than global involvement of the myocardium in this group
of patients. These findings allow identification and monitoring of
patients with HCM gene mutations before the development of
LVH.
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